Healthcare / BiotechnologyNasdaqGM
$2.74
-0.10 (-3.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-123.6M · quality 58.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$319M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-65.8%
↓Gross Margin
N/A
•Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2008–2025 · 17 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1685.8%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.6M · net income $-136.3M · FCF $-112.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||
| Revenue | $6.6M | $6.6M | $13.6M | $63.5M | $96.3M | $55.8M | $31.4M | $10.7M | $4.7M | $4.1M | $4.4M | $2.4M | — | $971000.00 | $2.7M | $1.2M | — | — | — |
| Net Income | $-136.3M | $-136.3M | $-186.3M | $-160.9M | $-281.7M | $-212.2M | $-173.4M | $-98.1M | $-66.6M | $-43.0M | $-33.5M | $-30.0M | $-25.9M | $-20.9M | $-14.2M | $-13.4M | $-16.2M | $-13.3M | $-7.2M |
| EBITDA | $-134.8M | $-134.8M | $-176.6M | $-172.2M | $-294.6M | $-211.1M | $-125.0M | $-98.5M | $-65.9M | $-41.2M | $-31.1M | $-27.1M | $-24.4M | $-17.1M | $-13.0M | $-12.6M | — | — | — |
| EPS | -1.15 | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -2222.4% | -2222.4% | -1434.5% | -299.9% | -320.2% | -388.6% | -407.5% | -943.1% | -1415.4% | -1025.9% | -726.1% | -1142.8% | — | -1820.3% | -507.8% | -1136.2% | — | — | — |
| Net Margin | -2051.1% | -2051.1% | -1366.5% | -253.3% | -292.5% | -379.9% | -551.6% | -919.0% | -1405.0% | -1046.1% | -760.2% | -1233.7% | — | -2151.8% | -533.3% | -1147.6% | — | — | — |
| Balance Sheet | |||||||||||||||||||
| Debt/Equity | 0.38 | 0.38 | 0.27 | 0.28 | 0.23 | — | — | — | 0.08 | 0.19 | 0.03 | 0.28 | 0.64 | 0.03 | -0.03 | — | — | — | — |
| Current Ratio | 5.85 | 5.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||
| Free Cash Flow | $-112.0M | $-112.0M | $-123.6M | $-138.4M | $-283.8M | $-213.6M | $-44.2M | $-90.6M | $-41.0M | $-38.5M | $-30.3M | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||||||
| ROE | -65.8% | -65.8% | -58.4% | -43.7% | -58.2% | -31.3% | -45.1% | -40.1% | -41.5% | -55.6% | -45.7% | -78.8% | -91.3% | -41.1% | 27.0% | 26.5% | 43.3% | 62.1% | 85.8% |
| Valuation | |||||||||||||||||||
| P/B | 1.57 | 1.57 | 0.64 | 1.01 | 0.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||
| Revenue Growth | -51.2% | -51.2% | -78.5% | -34.0% | — | 77.7% | 194.3% | 125.3% | 15.4% | -6.7% | 81.1% | — | — | -63.6% | 128.2% | — | — | — | — |
| EPS Growth | 29.9% | 29.9% | 0.0% | 43.6% | — | -6.7% | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+126.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.64 → -1.15
Residual
+126.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.